Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 3/20 | 0.43 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 2/20 | 0.34 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 2/20 | 0.33 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | NPR1 | P16066 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11816254 | 0.83 | AHR (0.43) | AHRBLMLMNAMAPTHTT | |
| SCHEMBL2177890 | 0.79 | LMNA (0.41) | AHRBLMLMNAMAPTHTT | |
| SCHEMBL9518303 | 0.75 | BLM (0.46) | AHRBLMLMNAMAPTHTT | |
| SCHEMBL1697236 | 0.74 | CYP3A4 (0.43) | MAPTCYP3A4CA2GSK3B | |
| SCHEMBL2809969 | 0.74 | GSK3B (0.33) | GSK3B | |
| SCHEMBL1383407 | 0.74 | GSK3B (0.31) | GSK3B | |
| SCHEMBL7158984 | 0.74 | LMNA (0.50) | LMNAMAPTCYP3A4TSHRTDP1 | |
| SCHEMBL6833886 | 0.74 | AHR (0.43) | AHRMAPTHTTPNMTMETAP1 | |
| SCHEMBL11694183 | 0.74 | CA1 (0.40) | MAPTCA2ADRA2AADRA2BADRA2C | |
| SCHEMBL17287441 | 0.74 | ADRA2A (0.34) | PNMTTDP2ADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4551680-A2 | METHODS OF MANUFACTURE OF R-MDMA | Mind Medicine, Inc. (US) | 2025-05-14 | — | — | EP | claimed |
| CN-119998433-A | Method for producing R-MDMA | 思维医学股份有限公司 | 2025-05-13 | — | — | CN | claimed |
| US-20240010628-A1 | METHODS OF MANUFACTURE OF R-MDMA | Mind Medicine, Inc. (US) | 2024-01-11 | — | — | US | claimed |
| WO-2024011067-A2 | METHODS OF MANUFACTURE OF R-MDMA | Mind Medicine, Inc. (US) | 2024-01-11 | — | — | WO | claimed |
| EP-4551680-A2 | METHODS OF MANUFACTURE OF R-MDMA | Mind Medicine, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| EP-4551680-A2 | METHODS OF MANUFACTURE OF R-MDMA | Mind Medicine, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-119998433-A | Method for producing R-MDMA | 思维医学股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-119998433-A | Method for producing R-MDMA | 思维医学股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-2024011067-A3 | METHODS OF MANUFACTURE OF R-MDMA | Mind Medicine, Inc. (US) | 2024-03-28 | — | — | WO | disclosed |
| US-20240010628-A1 | METHODS OF MANUFACTURE OF R-MDMA | Mind Medicine, Inc. (US) | 2024-01-11 | — | — | US | disclosed |
| US-20240010628-A1 | METHODS OF MANUFACTURE OF R-MDMA | Mind Medicine, Inc. (US) | 2024-01-11 | — | — | US | disclosed |
| WO-2024011067-A2 | METHODS OF MANUFACTURE OF R-MDMA | Mind Medicine, Inc. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-7105509-B2 | Benzodiazepine derivatives as APP modulators | MERCK SHARP & DOHME LIMITED (GB) | 2006-09-12 | — | — | US | disclosed |
| US-20040082572-A1 | Benzodiazepine derivatives as app modulators | MERCK SHARPE & DOHME LIMITED (GB) | 2004-04-29 | — | — | US | disclosed |
| US-20040023958-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2004-02-05 | — | — | US | disclosed |
| EP-1294702-A1 | BENZODIAZEPINE DERIVATIVES AS APP MODULATORS | MERCK SHARP & DOHME LTD. (GB) | 2003-03-26 | — | — | EP | disclosed |
| CN-1085980-C | Meta-guanidino, ureido, thioureido or azacyclic aminobenzoic acid derivatives as integrin antagonists | SEARLE & CO (US) | 2002-06-05 | — | — | CN | disclosed |
| WO-2001090084-A1 | BENZODIAZEPINE DERIVATIVES AS APP MODULATORS | MERCK SHARP & DOHME LIMITED (GB) | 2001-11-29 | — | — | WO | disclosed |
| US-4058607-A | DIHALOVINYL DIALKYL PHOSPHATE, 1,3-BENZODIOXOLES | AIRWICK INDUSTRIES, INC. (US) | 1977-11-15 | — | — | US | disclosed |
| US-3962415-A | Insecticide evaporator comprising DDVP with synergized benzodioxole compound as stabilizer | AIRWICK INDUSTRIES, INC. (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082572-A1 | Benzodiazepine derivatives as app modulators | BACE1, PSEN1, APP | AHR 1088/4885BLM 4752/4885LMNA 1324/4885 |
| US-20040023958-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | POLRMT, RNGTT, RNASE1 | AHR 2766/4885BLM 2021/4885LMNA 3489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.